Cerebral edema (brain swelling) is another very serious and often fatal adverse event encountered with CAR T treatment. Eight cerebral edema-related deaths have been reported to date. Reports of 5 …
CAR T-Cell Therapy HCP Guide – Side Effects: Cerebral Edema Read More
Neurotoxicity, which can occur in tandem with cytokine release syndome (CRS), includes symptoms such as aphasia, tremor, and seizures. Other reported CNS events include ataxia and confusion. The mechanisms leading …
CAR T-Cell Therapy HCP Guide – Side Effects: Neurotoxicity Read More
Cytokine Release Syndrome (CRS) is one of the most common, but worrisome, serious side effects of CAR T-cell therapy. How does it occur? After engineering, the CAR T-cells are reinfused …
CAR T-Cell Therapy HCP Guide – Side Effects: Cytokine Release Syndrome (CRS) Read More
CAR T-cell therapy is a potent investigational treatment used in patients with high tumor burden. A positive response to CAR T-cell therapy leads to difficult, but often reversible, side effects …
CAR T-Cell Therapy HCP Guide – Overview: Side Effects from CAR T-Cell Therapy Read More
While CAR T-cell therapy in hematologic cancers is impressive, the fact remains that most deadly cancers are solid tumors like lung, breast, or colon cancer. Efforts are ongoing to understand …
CAR T-Cell Therapy HCP Guide – Solid Tumor Research: Progress to Be Made Read More
Aggressive B Cell Non-Hodgkin Lymphomas About 90% of lymphoma cases start in the B cells. The C19 tumor target that is sought by the CAR T cell therapy is found …
CAR T-Cell Therapy HCP Guide – Pivotal Trial: Aggressive B-Cell Non-Hodgkin Lymphoma Read More
Gene Therapy to the Rescue The first investigational oncology gene therapy known as a chimeric antigen receptor (CAR) T-cell therapy is rapidly moving towards FDA approval. These agents — by …
CAR T-Cell Therapy HCP Guide – Cancer Targets Read More
CAR T-Cell Therapy and Checkpoint Inhibitors Together? CAR T-cell therapy positive response rates in aggressive leukemias and lymphomas are impressive, but relapse or progression does occur in some patients after …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 6 Trials Read More
CAR T-Cell Therapy for ALL Axicabtagene ciloleucel (KTE-C19) is also being investigated in the ZUMA-3 and ZUMA-4 trials for treatment of relapsed/refractory acute lymphoblastic leukemia (r/r ALL) in adult and …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 3 & 4 Trials Read More
ZUMA-2 Trial: Mantle Cell Lymphoma In the ZUMA-2 trial, Kite Pharma is also evaluating the treatment of relapsed/refractory mantle cell lymphoma (MCL) with KTE-C19. MCL is an aggressive B-cell lymphoma …
CAR-T Cell Therapy HCP Guide – KTE-C19 Studies – Zuma 2 Trials Read More